今日盘中,生物医疗公司Arcutis Biotherapeutics(ARQT.US)股价大涨7.98%,引发市场广泛关注。业内人士分析,主要原因是公司旗舰产品ZORYVE罗夫环乳膏治疗斑块状银屑病临床试验获得成功,潜力被看好,有望在国内也获批上市。
Arcutis Biotherapeutics公司主要从事免疫性皮肤病的新药研发,其主打产品ZORYVE罗夫环乳膏用于治疗斑块状银屑病,已在关键三期临床试验中证明了有效性和安全性。产品在海外市场已获批上市,如果能够进入潜力巨大的中国市场,将有望成为公司新的业绩增长点。
市场对Arcutis Biotherapeutics出口转内销的潜力给予了极大期待。据了解,公司正在筹备该产品国内注册申请的相关工作,一旦过关将打开中国斑块状银屑病患者的广阔市场。同时,公司也有望基于现有优势渗透到国内其他皮肤免疫性疾病的药物领域。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.